Madison, NJ, United States
Madison, NJ, United States

Time filter

Source Type

News Article | March 1, 2017
Site: www.24-7pressrelease.com

MORRISTOWN, NJ, March 01, 2017-- Dr. Jason E. Lowenstein, a Board Certified Morristown, NJ physician specializing in Orthopaedic Surgery, has been selected by Castle Connolly Medical Ltd. for inclusion in its authoritative guide to the top primary care and specialty care doctors in the tri-state metropolitan New York area.Morristown, NJ February 28, 2017-- Castle Connolly Medical Ltd., America's trusted source for identifying Top Doctors, has published the 15th edition of Top Doctors: New York Metro Area and has selected Jason E. Lowenstein, MD for this exclusive honor.The 15th edition of Top Doctors: New York Metro Area includes over 5,500 top primary care and specialty care physicians in a twenty-county area spanning three states: New York, New Jersey and Connecticut. Selected physicians, including Dr. Lowenstein, represent the top 10% of doctors in the area in 65 medical specialties and subspecialties for the care and treatment of more than 1,800 diseases and medical conditions.Castle Connolly Top Doctors are selected each year by Castle Connolly Medical Ltd. after being nominated by their peers in an online nomination process. Nominations are open to all board certified MDs and DOs and each year tens of thousands of physicians cast many tens of thousands of nominations. Nominated physicians are selected by the Castle Connolly physician-led research team based on criteria including medical education, training, hospital appointments, disciplinary histories and much more.About Jason E. Lowenstein:Dr. Jason E. Lowenstein is a board-certified, fellowship-trained, Adult and Pediatric Spine Surgeon. He is the Director of the Scoliosis and Spinal Deformity Center at Morristown Medical Center, and is a partner at The Advanced Spine Center in Morristown, NJ. ( www.theadvancedspinecenter.com ) Dr. Lowenstein specializes in the treatment of Spinal Deformity in children and adults, including Scoliosis, Kyphosis, and Spondylolisthesis, Disc Herniations and Stenosis of the Cervical, Thoracic, and Lumbar spine, Complex Revision Surgery for Failed Back Syndrome, and Minimally Invasive Spine Surgery.For more information on this Castle Connolly New York Metro Area Top Doctor , please visit Jason E. Lowenstein's profile on www.castleconnolly.com Castle Connolly Medical Ltd.'s President and CEO Dr. John Connolly has this to say about Dr. Lowenstein's recognition: "Roughly ten percent of area physicians were selected for our 15th edition of Top Doctors: New York Metro Area. Being nominated by Board Certified peers and then selected by our experts is an accomplishment worthy of recognition. The New York Metro area is home to a great number of very high quality medical professionals, yet some stand out. My congratulations to Dr. Lowenstein."To find out more or to contact Dr. Jason E. Lowenstein of Morristown, NJ, please call (973) 538-0900 or visit www.jasonlowensteinmd.com and/or www.theadvancedspinecenter.com This press release was written by American Registry, LLC and Castle Connolly Medical Ltd., with approval by and/or contributions from Jason E. Lowenstein.Castle Connolly Medical Ltd. identifies top doctors in America and provides consumers with detailed information about their education, training and special expertise in printed guides and online directories. It is important to note that doctors do not and cannot pay to be included in any Castle Connolly guide or online directory. Learn more at http://www.castleconnolly.com American Registry, LLC, recognizes excellence in top businesses and professionals. For more information, search The Registry at http://www.americanregistry.com


News Article | March 2, 2017
Site: www.prweb.com

Atlantic Health System announces the appointment of otolaryngologist and head and neck surgeon Tom Thomas, MD, MPH as medical director of head and neck reconstructive surgery and transoral robotic surgery for the Leonard B. Kahn Head & Neck Cancer Institute at Morristown Medical Center. Dr. Thomas, who joins head and neck surgeon Erik Cohen, MD, brings innovation and new talent to the Institute’s growing minimally invasive surgery program. A multidisciplinary team of specialists at the Leonard B. Kahn Head & Neck Cancer Institute evaluate and treat the entire spectrum of head and neck cancers, from early stage to the most complex advanced cancers of the throat, voice box, salivary glands, thyroid gland, mouth, lips, nose, and sinuses. Dr. Thomas comes to Atlantic Health System from Dana Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School, in Boston where he was the associate director of transoral robotic surgery (TORS). His focus is on minimally invasive surgical techniques such as TORS and Transoral Laser Microsurgery (TLM). “We are excited to have Dr. Thomas join our growing team of highly experienced head and neck specialists,” said Eric Whitman, MD, medical director, Atlantic Health System Cancer Care. “With Dr. Thomas and other nationally-known experts joining our team we are the most comprehensive and highly-skilled head and neck cancer program in New Jersey, and one of the strongest in the nation. “ Dr. Thomas has expertise in treating all head and neck cancers including but not limited to squamous cell carcinoma, basal cell carcinoma, melanoma, Merkel cell carcinoma, various salivary gland carcinomas, thyroid and parathyroid cancers, laryngeal cancers, sinus and skull base cancers. His minimally invasive surgical techniques, combined with a microvascular reconstructive surgical approach, helps to preserve important functions such as speech and swallowing that can be affected by head and neck cancer and its treatments. Dr. Thomas has extensive experience in Human Papilloma Virus (HPV) related head and neck cancer, especially oropharyngeal (tonsil and base of tongue) cancers. He lectures on this topic nationally and internationally. “I am excited to be part of a nationally ranked, magnet healthcare system where the leadership is focused on patient centered care and healthcare innovation,” said Dr. Thomas. “I am looking forward to working with our multidisciplinary head and neck cancer team and growing our head and neck cancer program as the best in the state and in the country.” Head and neck cancer is the sixth most common cancer in the U.S., with more than 60,000 new cases and over 13,000 deaths each year. Though tobacco and alcohol use can raise the risk of developing the disease, exposure to the human papillomavirus (HPV) poses an even greater risk. People who have had an oral HPV infection have a 50 times greater risk of developing head and neck cancer versus the general population. Currently, nearly three quarters of head and neck tumors test positive for HPV. A growing number of these newly diagnosed cases are among men in their forties and fifties.* Dr. Thomas received his medical degree from the Howard University College of Medicine with the highest academic honor of AOA (Alpha Omega Alpha). He completed his surgical internship at The Mayo Clinic in Rochester, MN, and his otolaryngology residency at the Barnes-Jewish Hospital/Washington University School of Medicine in St. Louis, MO. He then had additional fellowship training in head and neck surgical oncology, microvascular surgery and TransOral Robotic Surgery (TORS) at the Hospital of the University of Pennsylvania in Philadelphia. After completing his fellowship, he joined the medical staff at Dana Farber Cancer Institute and was associate surgeon at Harvard Medical School - Brigham and Women's Hospital in Boston. ‎In addition, he has a Master of Public Health degree from John Hopkins School of Public Health in Baltimore. He is affiliated with Atlantic Medical Group, and is a participating provider of Atlantic Accountable Care Organization. Dr. Thomas’s office is located at Morristown Medical Center, Carol G. Simon Cancer Center, Atlantic Center for Head & Neck Surgery, 100 Madison Avenue, First Floor, Morristown. For more information, call 973-971-7355 or go to atlantichealth.org/headneckcancer. About Atlantic Health System Atlantic Health System, headquartered in Morristown, New Jersey, is one of the largest non-profit healthcare systems in New Jersey. It includes Morristown Medical Center in Morristown, NJ; Overlook Medical Center in Summit, NJ; Newton Medical Center in Newton, NJ; Chilton Medical Center in Pompton Plains, NJ; and Goryeb Children’s Hospital in Morristown, NJ, as well as Atlantic Rehabilitation, and Atlantic Home Care and Hospice. It also includes its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System comprises 1,599 licensed beds, more than 14,000 employees and more than 4,000 physicians. Atlantic Health System has a medical school affiliation with the Sidney Kimmel Medical College at Thomas Jefferson University; a Major Clinical Affiliate of Rutgers Cancer Institute of New Jersey; part of Atlantic Accountable Care Organization, one of the largest ACOs in the nation, and is a member of AllSpire Health Partners.


News Article | February 21, 2017
Site: www.prweb.com

Two Atlantic Health System Hospitals were recognized in the top one and two percent of hospitals in the nation for clinical excellence by consumer rankings group Healthgrades.® Morristown Medical Center was the only hospital in the state to be recognized as one of ‘America’s 50 Best Hospitals’ for the second consecutive year. Overlook Medical Center was recognized as one of ‘America’s 100 Best Hospitals’ for the second consecutive year. The distinction places Morristown Medical Center in the top one percent and Overlook Medical Center in the top two percent of hospitals in the nation for clinical performance. The two hospitals were the only in New Jersey to be named to these prestigious lists. “Patients can be more secure in their decision to trust Atlantic Health System with their care, given our nationally recognized, consistent commitment to clinical excellence, patient safety, and patient outcomes,” said Trish O’Keefe, PhD, RN, president of Morristown Medical Center. “We make a strong effort to align our medical staff and care teams to deliver exceptional care in a healing environment, and are proud to be recognized for this daily commitment.” “As health care becomes ever more focused on value, the national recognition for Atlantic Health System’s high quality, patient-centered care makes us a clear choice for patients,” said Alan Lieber, president of Overlook Medical Center. “From cutting edge technology to the care teams who guide our patients’ continuum of care inside and outside our walls, our relentless commitment to clinical excellence and patient outcomes is evident at every level.” “The Healthgrades analysis of clinical outcomes shows that there is tremendous variation in care, so it’s important for consumers to research and select a hospital that will provide high-quality care,” said Brad Bowman, chief medical officer, Healthgrades. The recipients of the America’s 50 Best Hospitals Award™ and America’s 100 Best Hospitals Award™ stand out among the rest for overall clinical excellence across a broad spectrum of care. During the 2017 study period (2013-2015), these hospitals showed superior performance in clinical outcomes for patients in the Medicare population across at least 21 of 32 most common inpatient conditions and procedures — as measured by objective performance data (risk-adjusted mortality and in-hospital complications). To learn more about how Healthgrades determines America’s 50 Best Hospitals Award™ recipients, please visit http://www.healthgrades.com/quality. *Statistics are based on Healthgrades analysis of MedPAR data for years 2013 through 2015 and represent 3-year estimates for Medicare patients only. For more information on methodology, visit http://www.healthgrades.com/quality. About Atlantic Health System Atlantic Health System, headquartered in Morristown, New Jersey, is a leading non-profit health care delivery system in New Jersey. Our network includes Morristown Medical Center in Morristown, NJ; Overlook Medical Center in Summit, NJ; Newton Medical Center in Newton, NJ; Chilton Medical Center in Pompton Plains, NJ; Hackettstown Medical Center in Hackettstown, NJ; and Goryeb Children’s Hospital in Morristown, NJ, as well as Atlantic Rehabilitation, and Atlantic Home Care and Hospice. It also includes its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System comprises 1,747 licensed beds, more than 14,000 employees and more than 4,000 physicians. Atlantic Health System has a medical school affiliation with the Sidney Kimmel Medical College at Thomas Jefferson University; is part of Atlantic Accountable Care Organization, one of the largest ACOs in the nation, and is a member of AllSpire Health Partners.


News Article | February 16, 2017
Site: www.prweb.com

Atlantic Health System’s Annual Heart Failure Awareness Week Symposium will highlight the latest research, programs, and clinical advances in heart failure. The 6th annual, day-long scientific symposium, to be held on February 17, during National Heart Failure Awareness Week, will feature ten Atlantic Health System clinicians presenting on topics including: Claire G. Boccia Liang, MD, FACC, Director of the Women’s Heart Program at Atlantic Health System, will present a keynote on congenital heart disease. “As a nationally recognized leader in cardiology, Atlantic Health System is committed to ensuring that its medical teams have access to the latest research, technology, and care delivery models so patients with heart failure receive optimal treatment that will both prolong and improve the quality of life,” said Linda Gillam, MD, MPH, chair, Department of Cardiovascular Medicine, Atlantic Health System. “The Annual Heart Failure Awareness Week Symposium also affords attendees a chance for discussion and healthy debate among multi-disciplinary care teams.” Atlantic Health System, headquartered in Morristown, New Jersey, is a leading non-profit health care delivery system in New Jersey. Our network includes Morristown Medical Center in Morristown, NJ; Overlook Medical Center in Summit, NJ; Newton Medical Center in Newton, NJ; Chilton Medical Center in Pompton Plains, NJ; Hackettstown Medical Center in Hackettstown, NJ; and Goryeb Children’s Hospital in Morristown, NJ, as well as Atlantic Rehabilitation, and Atlantic Home Care and Hospice. It also includes its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System comprises 1,747 licensed beds, more than 14,000 employees and more than 4,000 physicians. Atlantic Health System has a medical school affiliation with the Sidney Kimmel Medical College at Thomas Jefferson University; is part of Atlantic Accountable Care Organization, one of the largest ACOs in the nation, and is a member of AllSpire Health Partners.


LOUISVILLE, Ky. & MORRISTOWN, N.J.--(BUSINESS WIRE)--Kindred Healthcare, Inc. (“Kindred”) (NYSE:KND) and Atlantic Health System today announced the signing of a definitive agreement to create a joint venture to construct and operate a 38-bed inpatient rehabilitation hospital in northern New Jersey. The new facility will offer all private rooms, supporting both enhanced clinical efficiency and elevated patient experience with targeted clinical programs including neurological, spine, trauma and complex conditions. The growth in trauma cases and the increased level of acuity of patients served by Atlantic Health System has resulted in more patients requiring inpatient rehabilitation services in order to improve their functional status prior to returning home. The combination of Kindred’s expertise and a modern, state-of-the-art facility will allow Atlantic Health System to maximize its ability to serve a growing population of patients with critical needs. Subject to several regulatory and other approvals, Kindred and Atlantic Health System expect the rehabilitation facility to open by the fourth quarter of 2018. The new hospital will enhance Kindred’s existing services in New Jersey, which include three long-term acute care (“LTAC”) hospitals and hospice services. “We are confident that our partnership with Atlantic Health System, New Jersey’s premier health system, will address the growing need for inpatient rehabilitation services in the New Jersey and New York area as we build and operate a new facility together,” said Jason Zachariah, President of Kindred Rehabilitation Services, a division of Kindred. “This quality-focused collaboration with a leading healthcare system will deliver the kind of excellent care that improves patients’ lives and enables our inpatient rehabilitation business to continuously outperform peers in key clinical measures.” “By joining together with Kindred, which has a proven record of industry-leading clinical outcomes, we are expanding a service that our community needs and deserves,” said Brian Gragnolati, President and Chief Executive Officer, Atlantic Health System. “A dedicated inpatient rehabilitation hospital designed to promote healing will bring a higher level of care to improve the lives of our patients and their families.” Kindred Healthcare, Inc., a top-90 private employer in the United States, is a FORTUNE 500 healthcare services company based in Louisville, Kentucky with annual revenues of approximately $7.2 billion(1). As of October 1, 2016, Kindred through its subsidiaries had approximately 102,200 employees providing healthcare services in 2,702 locations in 46 states, including 82 LTAC hospitals, 19 inpatient rehabilitation hospitals, 91 nursing centers, 19 sub-acute units, 647 Kindred at Home home health, hospice and non-medical home care sites of service, 104 inpatient rehabilitation units (hospital-based) and contract rehabilitation service businesses which served 1,740 non-affiliated sites of service. Ranked as one of Fortune magazine’s Most Admired Healthcare Companies for seven years, Kindred’s mission is to promote healing, provide hope, preserve dignity and produce value for each patient, resident, family member, customer, employee and shareholder we serve. For more information, go to www.kindredhealthcare.com. You can also follow us on Twitter and Facebook. Atlantic Health System, headquartered in Morristown, New Jersey, is a leading non-profit health care delivery system in New Jersey. Our network includes Morristown Medical Center in Morristown, NJ; Overlook Medical Center in Summit, NJ; Newton Medical Center in Newton, NJ; Chilton Medical Center in Pompton Plains, NJ; Hackettstown Medical Center in Hackettstown, NJ; and Goryeb Children’s Hospital in Morristown, NJ, as well as Atlantic Rehabilitation, and Atlantic Home Care and Hospice. It also includes its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System comprises 1,747 licensed beds, more than 14,000 employees and more than 4,000 physicians. Atlantic Health System has a medical school affiliation with the Sidney Kimmel Medical College at Thomas Jefferson University; is part of Atlantic Accountable Care Organization, one of the largest ACOs in the nation, and is a member of AllSpire Health Partners.


MORRISTOWN, NJ, October 28, 2016-- Castle Connolly Medical Ltd., America's trusted source for identifying Top Doctors, has selected Morristown's Orthopaedic Surgery specialist Dr. Jason E. Lowenstein, MD for inclusion in its highly selective list of Castle Connolly Top Doctors this year.Castle Connolly Medical Ltd. publishes its list of Castle Connolly Top Doctors at www.castleconnolly.com , as well as in a wide variety of printed directories, partner publications and on partner/affiliate websites. All told, more than 44,000 physicians - approximately 5% of the nation's licensed physicians - have been selected as Castle Connolly Top Doctors in their regions for their specialties.Castle Connolly Top Doctors are selected by Castle Connolly Medical Ltd. after being nominated by peer physicians in an online nomination process. Nominations are open to all board certified MDs and DOs and each year tens of thousands of doctors cast many tens of thousands of nominations. Honorees are selected from the nominees by the Castle Connolly physician-led research team based on criteria including their medical education, training, hospital appointments, disciplinary histories and more.About Jason E. Lowenstein, MD:Dr. Jason E. Lowenstein is a board-certified, fellowship-trained, Adult and Pediatric Spine Surgeon. He is the Director of the Scoliosis and Spinal Deformity Center in the Department of Orthopaedic Surgery at Morristown Medical Center in Morristown, NJ. Dr. Lowenstein specializes in the treatment of Spinal Deformity in both children and adults, including Scoliosis, Kyphosis, and Spondylolisthesis, Disc Herniations and Stenosis of the Cervical, Thoracic, and Lumbar spine, Complex Revision Surgery for Failed Back Syndrome, and Minimally Invasive Spine Surgery.For more information on this Castle Connolly Top Doctor, please visit Jason E. Lowenstein, MD's profile on www.castleconnolly.com Castle Connolly Medical Ltd.'s President and CEO Dr. John Connolly has this to say about Dr. Lowenstein's recognition: "Only a small percent of physicians are selected to be Castle Connolly Top Doctors. Our goal is to make it easier for an average person to find the right doctor for them in what can be an overwhelming process at a difficult time in a person's life. Dr. Lowenstein was nominated by physician peers and selected by our physician-led research team at Castle Connolly Medical Ltd. Selection is an impressive accomplishment worthy of recognition. My congratulations to Dr. Lowenstein."To find out more or to contact Dr. Jason E. Lowenstein, MD of Morristown, NJ, please call (973) 538-0900 or visit www.jasonlowensteinmd.com and/or www.theadvancedspinecenter.com This press release was written by American Registry, LLC and Castle Connolly Medical Ltd., with approval by and/or contributions from Jason E. Lowenstein, MD.Castle Connolly Medical Ltd. identifies top doctors in America and provides consumers with detailed information about their education, training and special expertise in printed guides, online directories, and through its partnerships with more than 50 city and regional magazines and major newspapers all across the United States. It is important to note that doctors do not and cannot pay to be selected as a Castle Connolly Top Doctor. Learn more at www.castleconnolly.com American Registry, LLC, recognizes excellence in top businesses and professionals. For more information, search The Registry at http://www.americanregistry.com


One of New Jersey’s Top Orthopedic Spine Surgeons Talks about the Latest Trends. Morristown, NJ, December 23, 2016 --( He is no stranger to innovation. He was the first orthopedic spine surgeon in New Jersey to use SYNTHESIS Cervical Total Disc Replacement and an early adopter of O-Arm Surgical Imaging System, which provides real-time, intraoperative imaging of a patient's anatomy with high quality images to make surgery safer. In each case there was compelling data and published reports with favorable results about these innovations to support their usage, and they made sense. This is part of the methodical process he uses any time he adopts a new technique or uses a new instrument for surgery. As a spine surgeon with more than 15 years of experience in all disorders of the spine, he doesn’t jump on the bandwagons of trends. By using methods that he’s used to perform countless surgeries, he’s saved lives and restored patients’ quality of life, whether it be chronic back pain or life-changing-or-threatening trauma. “There is no epiphany on how to treat back pain,” Richard Nachwalter, M.D., said. “Doctors know the most effective way to perform which procedure for which ailment based on a history of efficacy and safety. At Atlantic Spine Specialists, we always stay updated on what’s happening in orthopedic spine surgery. We only use gold standards of surgery, so we adopt a new technique once there is sufficient evidence that proves its effectiveness and safety.” Richard Nachwalter, M.D., served as the first chairman of the Spine New Technology Committee at Atlantic Health. He also serves on the Spine Steering committee and served on the Orthopedic advisory committee. He has recently been appointed to the Operating Room Committee at Morristown Medical Center. As a member of Atlantic Spine Specialists, he [and partner Carl Giordano, M.D.] utilize minimally invasive techniques, microscopic surgical techniques, and traditional surgery as well. For more information about Richard Nachwalter, M.D., you can visit http://atlanticspinespecialists.com/meet-richard-nachwalter-md/. About Atlantic Spine Specialists Atlantic Spine Specialists features board-certified, fellowship-trained spine surgeons. Located in Morristown, NJ, with a satellite office in Westfield, NJ; Atlantic Spine Specialists perform their procedures in Morristown Medical Center, a spine center of excellence. This facility is one of the few to earn this distinction from the Joint Commission on Accreditation of Healthcare Organizations (JCAHO). For more information about Atlantic Spine Specialists, you can visit their website at http://atlanticspinespecialists.com/ or call 973-971-3500. About GWP Inc GWP Inc., founded in 1991, is a full-service advertising agency in the heart of Montclair, NJ with a focus in Rebranding, Rebuilding and Revitalizing businesses. Among our in-house capabilities, are online and traditional media planning and buying, video production, online marketing, TV, radio and print creative and production. GWP is a boutique agency with five divisions, working independently and/or in concert to deliver strategically sound, creatively crafted, targeted campaigns. For more information about GWP Inc., visit their website at http://gwpinc.com/ or call 973-746-0500. Morristown, NJ, December 23, 2016 --( PR.com )-- Richard Nachwalter, M.D., a leading orthopedic spine surgeon and part of Atlantic Spine Specialists in Morristown, NJ; appreciates innovation, but when it comes to innovation for surgery, it’s not about being the first.He is no stranger to innovation. He was the first orthopedic spine surgeon in New Jersey to use SYNTHESIS Cervical Total Disc Replacement and an early adopter of O-Arm Surgical Imaging System, which provides real-time, intraoperative imaging of a patient's anatomy with high quality images to make surgery safer. In each case there was compelling data and published reports with favorable results about these innovations to support their usage, and they made sense. This is part of the methodical process he uses any time he adopts a new technique or uses a new instrument for surgery.As a spine surgeon with more than 15 years of experience in all disorders of the spine, he doesn’t jump on the bandwagons of trends. By using methods that he’s used to perform countless surgeries, he’s saved lives and restored patients’ quality of life, whether it be chronic back pain or life-changing-or-threatening trauma.“There is no epiphany on how to treat back pain,” Richard Nachwalter, M.D., said. “Doctors know the most effective way to perform which procedure for which ailment based on a history of efficacy and safety. At Atlantic Spine Specialists, we always stay updated on what’s happening in orthopedic spine surgery. We only use gold standards of surgery, so we adopt a new technique once there is sufficient evidence that proves its effectiveness and safety.”Richard Nachwalter, M.D., served as the first chairman of the Spine New Technology Committee at Atlantic Health. He also serves on the Spine Steering committee and served on the Orthopedic advisory committee. He has recently been appointed to the Operating Room Committee at Morristown Medical Center. As a member of Atlantic Spine Specialists, he [and partner Carl Giordano, M.D.] utilize minimally invasive techniques, microscopic surgical techniques, and traditional surgery as well. For more information about Richard Nachwalter, M.D., you can visit http://atlanticspinespecialists.com/meet-richard-nachwalter-md/.About Atlantic Spine SpecialistsAtlantic Spine Specialists features board-certified, fellowship-trained spine surgeons. Located in Morristown, NJ, with a satellite office in Westfield, NJ; Atlantic Spine Specialists perform their procedures in Morristown Medical Center, a spine center of excellence. This facility is one of the few to earn this distinction from the Joint Commission on Accreditation of Healthcare Organizations (JCAHO). For more information about Atlantic Spine Specialists, you can visit their website at http://atlanticspinespecialists.com/ or call 973-971-3500.About GWP IncGWP Inc., founded in 1991, is a full-service advertising agency in the heart of Montclair, NJ with a focus in Rebranding, Rebuilding and Revitalizing businesses. Among our in-house capabilities, are online and traditional media planning and buying, video production, online marketing, TV, radio and print creative and production. GWP is a boutique agency with five divisions, working independently and/or in concert to deliver strategically sound, creatively crafted, targeted campaigns. For more information about GWP Inc., visit their website at http://gwpinc.com/ or call 973-746-0500. Click here to view the list of recent Press Releases from Atlantic Spine Specialists


Slomovitz B.M.,Morristown Medical Center | Slomovitz B.M.,University of Houston | Coleman R.L.,University of Houston
Clinical Cancer Research | Year: 2012

Endometrial cancer is the most common gynecologic malignancy in the United States. Overactivation of the PI3K/AKT/mTOR pathway, a signaling pathway that plays an important role in cellular growth and survival, has recently been implicated in endometrial cancer pathogenesis, and as such, inhibition of the PI3K/AKT/mTOR pathway is of therapeutic interest. Preclinical and clinical studies are proving useful in elucidating the antitumor effects of different PI3K/AKT/mTOR pathway inhibitors, and in defining which patient populations these inhibitors might be most effective in. For example, an increasing amount of preclinical data suggest that loss of PTEN or genetic alteration of PIK3CA may be indicators of sensitivity to PI3K/AKT/mTOR pathway inhibition, while activating KRAS mutations may predict resistance. In the latter case, combined inhibition of the RAS/RAF/MEK and PI3K/AKT/mTOR pathways has been suggested as a therapeutic strategy. In addition, the PI3K/AKT/mTOR pathway has been implicated in conferring resistance to conventional therapies, and so PI3K/AKT/mTOR pathway inhibitors in combination with hormonal and/or cytotoxic agents are being evaluated. In conclusion, preclinical models are providing insights into the antitumor activity of PI3K/AKT/mTOR pathway inhibition, and are helping define patient populations most likely to benefit from these therapies. Clinical validation of these findings is ongoing. ©2012 AACR.


Fiel S.B.,Morristown Medical Center
Expert Review of Respiratory Medicine | Year: 2014

Inhaled antibiotic therapy, targeting Pseudomonas aeruginosa, is a fundamental component of cystic fibrosis (CF) management. Tobramycin inhalation solution (TIS) was approved in the United States (US) in 1998. Subsequent research efforts focused on developing products with a reduced treatment time burden. Aztreonam for inhalation solution (AZLI), administered via a more efficient nebulizer than TIS, was approved in the US in 2010. Dry powder for inhalation (DPI) formulations provide alternatives to nebulized therapy: tobramycin powder for inhalation (also known as TIP™) was approved in the US in 2013, and colistimethate sodium DPI received European approval in 2012. Other aerosolized antibiotics and regimens combining inhaled antibiotics are in development. Inhaled antibiotic rotation (e.g., TIS alternating with AZLI) is an important concept being actively tested in CF. © Informa Uk, Ltd.


NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTCQB:TYMI), a specialty biotechnology company developing cancer therapeutics targeted at multiple tumor types, today announced the addition of Paul L. Sturman, a seasoned pharmaceutical executive with 30 years in the consumer health industry at Pfizer, Johnson & Johnson and Warner Lambert, to the company’s board of directors. “As Tyme transforms from being an early-stage biotech company to a more fully integrated one, Paul’s expertise in managing complex organizations and building corporate culture will be invaluable,” said CEO Steve Hoffman.  “Throughout his career in large pharma, Paul has a track record of consistently delivering growth in revenue, profitability and market share, underscored by a lifelong commitment to improving quality of healthcare and access through education.  We look forward to his extensive experience and board leadership as we move forward.” Mr. Sturman has worked in the healthcare industry in a variety of leadership positions.  At Pfizer, Mr. Sturman ran the Global Consumer Healthcare division, one of the largest over-the-counter healthcare products companies in the world. He also previously served as President of J&J’s North American Consumer Health division as well as numerous leadership roles in marketing, brand, and sales management with Warner Lambert.  He is a member of the Board of Trustees of the Foundation for Morristown Medical Center, one of “America’s Top 50 Hospitals,” which works to advance healthcare for patients by preserving and expanding programs and services in patient care, clinical research, medical and public health education, and preventive medicine. About Tyme Tyme Technologies is developing a novel first-in-class therapy, SM-88, that is designed to use cancer’s unusual metabolism to selectively break down the cellular defenses of tumors, leading to tumor cell death. Through clinical trials and expanded access programs, SM-88 has been used in over 84 individuals and shown a clinical response in thirteen cancer types. In its initial Phase I trial for end-stage, metastatic cancer patients, SM-88 treatment resulted in a median overall survival of 26 months, with 32% of patients alive at the end of the three year evaluation period without any drug-related serious adverse events. The Company is currently conducting a Phase Ib/II trial in prostate cancer in addition to ongoing collaborations with the Mayo Clinic, Mount Sinai, the Albert Einstein College of Medicine and other institutions. For more information, visit our website: www.tymeinc.com. Forward-Looking Statements/Disclosure Notice In addition to historical information, this press release contains forward-looking statements that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidates (including SM-88), our drug development plans and strategies, our completed and planned clinical trials and the therapeutic design and mechanisms of our drug candidates; and readers can identify forward-looking statements by sentences or passages involving the use of terms such as “anticipates,” “believes,” “designed,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Tyme’s control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties inherent in research and development, including the ability to achieve clinical study start and completion dates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final Phase 1b data analysis, final results of additional clinical trials, or both, may be different from the preliminary data analysis and may not support further clinical development; whether and when any applications or other submissions for SM-88 may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88; competitive developments; and the factors described in the section captioned “Risk Factors” of Tyme’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 30, 2016 (available at www.sec.gov). The information contained in this press release is as of January 31, 2017 and Tyme assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.

Loading Morristown Medical Center collaborators
Loading Morristown Medical Center collaborators